Guided Therapeutics Granted Additional Key Patent for LuViva® Advanced Cervical Scan

Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that U.S. Patent and Trademark Office granted a new patent with 22 claims that support the technology behind the LuViva® Advanced Cervical Scan. Patent number 8,781,560 B2 entitled “Method and...

Guided Therapeutics’ LuViva® Advanced Cervical Scan Awarded Mexican Regulatory Approval

Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that LuViva® Advanced Cervical Scan was approved for sale in Mexico by the Federal Commission for Protection against Health Risks (COFEPRIS). “Approval to sell LuViva in Mexico is a significant...

Guided Therapeutics Second Quarter Sales to Reach $200,000; Update Timing for Amended PMA Application for LuViva® Advanced Cervical Scan

Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today provided anticipated sales results for its second quarter ended June 30, 2014 and also provided updated timing regarding the submittal of its amendment to its premarket approval (PMA) application for the...

Guided Therapeutics’ LuViva® Advanced Cervical Scan Wins Prestigious Medical Design Award

The LuViva® Advanced Cervical Scan was chosen as best designed new medical device of 2014 at the 17th Annual Medical Device Excellence Awards (MDEA) ceremony held Wednesday, June 11, 2014, in conjunction with the MD&M East event at the Jacob K. Javits Convention...

Guided Therapeutics to Present at LD Micro Invitational Conference on Wednesday, June 4

Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) developer of the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease that leads to cancer, today announced that Gene Cartwright, the Company’s CEO, will be a featured presenter at...